AbbVie
Global biopharmaceutical company developing medicines
Business Technology Solutions Intern - Data & Software Engineering, Undergraduate
11-week onsite internship; placements may be at other U.S. AbbVie or Allergan Aesthetics locations based on business need.
About the job
- Pursuing a Bachelor's degree in Computer Science, Computer Engineering, AI, or a related major, with a minor or concentration in one of these fields.
- Graduating between December 2027 and June 2028.
- Remaining enrolled at a university during the semester following the internship and graduating within one year after the internship.
- Design, build, test, maintain, and optimize enterprise applications, data infrastructure, databases, and data pipelines across the assigned engineering track.
- Develop, test, and maintain interactive and responsive front-end user interfaces.
- Build backend services, application programming interfaces, and microservices using Java and Spring Boot.
- Implement server-side logic, workflows, and data pipelines while optimizing performance, scalability, and reliability.
- Own front-end and back-end components end to end for full-stack solutions.
- Support the design and development of data, software, or technology solutions addressing scientific or business questions.
- Use technologies for programming, data integration, data warehousing, data visualization, and data analysis.
- Ensure data is collected, processed, and stored efficiently and securely.
- Integrate different data sources and create foundations for analytics and data science.
- School or work experience with Node.js, Vue.js, HTML, Java, JavaScript, SQL, TypeScript, APEX, or Python.
- Ability to apply generative artificial intelligence to custom software solutions.
- A public code portfolio on GitHub, GitLab, or Bitbucket.
- Strong programming experience in Java, Python, R, and SQL for the Data Engineering track.
- Experience using application programming interfaces to extract data and applying large language models or machine learning algorithms.
- Previous internship or related experience.
- Technical and business insight, analytical skills, creative problem-solving abilities, teamwork, adaptability, innovation, initiative, and integrity.
- Communication, leadership, and project management skills.
- Cumulative GPA of 3.00 or higher.
About the company
AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
Get referred to AbbVie
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue hit $16.99 billion; adjusted EPS rose 22.9% year over year.
- Skyrizi reached $5.505 billion and Rinvoq $2.525 billion in Q2 2026, both growing 24%+.
- RINVOQ gained EU approvals for pediatric arthritis, vitiligo, alopecia, and new AI discovery.
What critics are saying
- Humira fell to $756 million in Q2 2026; the decline keeps dragging.
- Dupixent from Sanofi and Regeneron attacks AbbVie’s eczema and inflammation growth through 2027.
- Skyrizi and Rinvoq fund everything; pipeline failures before 2030 would crush valuation.
What makes AbbVie unique
- AbbVie owns a rare post-Humira cash machine: Skyrizi and Rinvoq.
- AbbVie keeps expanding immunology with Apogee and Capstan acquisitions in September 2026.
- AbbVie pairs scale with specialty depth across immunology, neuroscience, oncology, and aesthetics.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Flexible Work Hours
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 5%2 year growth
↑ 5%The European Commission has approved RINVOQ (upadacitinib) for treating active polyarticular juvenile idiopathic arthritis in patients aged two years and older who have not responded adequately to one or more disease-modifying anti-rheumatic drugs. AbbVie announced the approval includes a new oral solution formulation alongside the tablet form. The approval was based on the open-label Phase 1 SELECT-YOUTH study and adult rheumatoid arthritis data. In the study of 122 patients, 79.5% achieved 70% improvement in disease activity at week 48, whilst 43.4% achieved remission. No new safety risks were identified during the trial period. Juvenile idiopathic arthritis affects approximately 126,000 children in Europe. RINVOQ is now approved in the European Union for 11 indications across various immune-mediated inflammatory diseases.
ADARx Pharmaceuticals has priced its initial public offering of 21.875 million shares between $15.00 and $17.00 per share, according to an SEC filing. The San Diego-based late-clinical stage biotechnology company has applied to list on Nasdaq under the ticker "ADRX". AbbVie has agreed to purchase shares in a concurrent private placement that would give it approximately 4.9% ownership of ADARx's outstanding stock. Underwriters have a 30-day option to purchase up to 3.28 million additional shares. The company estimates net proceeds of approximately $397.1 million, or $445.9 million if underwriters exercise their option in full, assuming a $16.00 share price. Proceeds will fund clinical trial development and general corporate purposes.
AbbVie and Iambic Therapeutics have entered into a multi-year collaboration to accelerate AI-driven drug discovery in immunology, neuroscience, and oncology. The partnership will combine Iambic's molecular superintelligence platform with AbbVie's therapeutic expertise to develop small molecule therapies with first-in-class and best-in-class potential. The collaboration will utilise Enchant v3, Iambic's next-generation multimodal transformer model trained on over 6,000 molecular properties. This technology is designed to optimise candidate properties simultaneously, reducing drug discovery timelines whilst improving success rates. Under the agreement, Iambic will receive an upfront payment and is eligible for success-based milestone payments and tiered royalties on net sales from products generated through the collaboration. The partnership aims to accelerate the discovery process and deliver breakthrough medicines to patients more quickly.
September 21, 2026 AbbVie and Iambic announce collaboration to accelerate AI-driven drug discovery. * Multi-year partnership applies Iambic's AI platform to speed up small molecule drug discovery in immunology, neuroscience and oncology * Companies to pursue programs with both first-in-class and best-in-class potential, combining Iambic's molecular superintelligence platform with AbbVie's therapeutic area expertise NORTH CHICAGO, Ill. and SAN DIEGO, Sept. 21, 2026 /PRNewswire/ - AbbVie (NYSE: ABBV) and Iambic, a clinical-stage life sciences and technology company developing novel medicines through its AI-driven discovery and development platform, today announced a multi-year collaboration to accelerate the discovery and development of small molecule therapies with first-in-class and best-in-class potential across immunology, neuroscience and oncology. The companies will leverage Iambic's AI platform to improve the efficiency and success of identifying promising new drug candidates. "We are excited about the purpose-built AI capabilities Iambic is bringing to our Discovery scientists," said Nicholas Donoghoe, M.D., executive vice president and chief business and strategy officer, AbbVie. "We believe AI will be a powerful catalyst for scientific innovation across AbbVie. By equipping our teams with fit-for-purpose AI solutions, we can accelerate discovery, expand what is possible in R&D and significantly advance our commitment to making a remarkable impact for patients." "Combining Iambic's platform with the drug-hunting expertise of AbbVie scientists can help us make more precise decisions about the molecules we pursue," said Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research, AbbVie. "The goal of our collaboration with Iambic is to design better molecules more efficiently and improve our probability of success, ultimately to deliver breakthrough medicines for patients sooner." In traditional small molecule discovery, scientists evaluate dozens of properties for each candidate individually. Iambic's molecular superintelligence platform is powered by Enchant and NeuralPLexer, technologies designed to optimize the full range of candidate properties simultaneously, increasing the chance of making better molecules while reducing drug discovery timelines. The collaboration will utilize Enchant v3, Iambic's next-generation multimodal transformer model that combines biomedical data modalities from across the drug discovery process and enables many drug design hypotheses to be tested in parallel and at scale. Enchant v3 is designed to achieve industry-leading prediction accuracy across drug discovery and development and is trained on over 6,000 molecular properties. "Iambic's mission is to make better technology for better medicines - in our own hands and with partners," said Tom Miller, Ph.D., Co-Founder and CEO, Iambic. "We are eager to bring Iambic's molecular superintelligence platform to bear alongside AbbVie's world-class team to address unmet patient need. We anticipate an impactful collaboration - for Iambic, for AbbVie, and for the patients we serve."
Acquisition adds a potential first-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T therapy candidate for B cell-mediated autoimmune diseases as well as a proprietary tLNP...